Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Intestinal infections
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.